Andira is a private pharmaceutical technology company commercializing breakthrough advancements for infection control.

  • Andira uses a validated R&D platform to transform existing pharmaceutical agents into advanced next-generation solutions with improved efficacy by harnessing pharmacologic synergy.
  • Andira is targeting near-term market approval of Matrix3™ Shield for infection control in advanced wound care.
  • Andira has multiple healthcare innovations in its pipeline and holds a global portfolio of patented and patent-pending breakthroughs for infection control, cancer therapy, pain management and enhanced drug delivery. 
WE ARE ANDIRA PHARMACEUTICALS

Andira endeavors to raise the medical standard of care with its breakthrough patented and patent-pending technologies by delivering next-generation healthcare products.

Andira is uniquely positioned as the only company having two validated triple synergy anti-bacterial technologies that contain standard-of-care infection control agents that are approved and already in use worldwide.

Andira’s lead product for infection control is Matrix3™ Shield, an anti-infective medical device for advanced wound care. The breakthrough technology backing the product is Matrix3™, a triple synergy silver-based agent for the prevention and treatment of infections, including those caused by antibiotic resistant “superbug” bacteria.

Matrix3™ has shown over 1,000,000 times better performance and faster onset of action than silver alone  – a mainstay infection control agent incorporated into healthcare products globally. Silver-based Matrix3™ anti-infective technology is suitable for use in medical devices, wound care, surface coatings and topically-applied drug products. For example, wound dressings formulated with silver for infection control are a $1 billion USD global market. Learn more about Matrix3™ and Andira’s portfolio of pharmaceutical technologies below.

Product Development

Matrix3™ for Infection Control

Andira’s anti-infective Matrix3TM triple synergy technology provides faster onset and improved efficacy against drug-resistant bacteria including MRSA and Pseudomonas. Matrix3TM Shield is Andira’s lead infection control product for advanced wound care.

Hospital Acquired Infections

Our Hospital Infections program is advancing an injectable product for Drug-Resistant Enterococcus (“VRE”) – a life-threatening hospital-acquired infection.

Oncology

Andira uses the most translational research techniques available to optimize treatments to address Metastatic Breast Cancer.

COMPANY NEWS AND EVENTS

Latest News